Immunotoxin therapy for hematologic malignancies: where are we heading?

被引：20
|
作者：
Madhumathi, Jayaprakasam [1 ]
Devilakshmi, Sithambaram [1 ]
Sridevi, Surapally [1 ]
Verma, Rama S. [1 ]
机构：
[1] Indian Inst Technol, Stem Cell & Mol Biol Lab, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Chennai 600036, Tamil Nadu, India
来源：
DRUG DISCOVERY TODAY | 2016年 / 21卷 / 02期
关键词：
ACUTE LYMPHOBLASTIC-LEUKEMIA; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; HAIRY-CELL LEUKEMIA; MEDIATES POTENT APOPTOSIS; TARGETED CANCER-THERAPY; PHASE-I TRIAL; RECOMBINANT IMMUNOTOXIN; RFB4(DSFV)-PE38 BL22; SINGLE-CHAIN;
D O I：
10.1016/j.drudis.2015.05.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The identification of numerous unique targets in recent years has led to the development of various immunotoxins (ITs) for treating hematological malignancies. Some of these ITs have advanced to clinical trials and have resulted in a high response rate against leukemia. Newer targets with improve specificity are also being identified for targeting several leukemias. Currently, several modified versions of ITs with increased efficacy are being constructed and evaluated for cytotoxicity in vitro as well as in vivo. Here, we summarize recent advances in preclinical and clinical studies of recombinant ITs targeting diverse surface receptors.
引用
收藏
页码：325 / 332
页数：8
相关论文
共 50 条
  • [41] Naturopathy in Australia: Where are we now? Where are we heading?
    Ooi, Soo Liang
    McLean, Lisa
    Pak, Sok Cheon
    COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2018, 33 : 27 - 35
  • [42] International cooperation. Where are we, and where are we heading to?
    Kattan, Eduardo
    Kuroiwa, Aron
    Lopez, Rodrigo
    REVISTA MEDICA DE CHILE, 2017, 145 (06) : 783 - 789
  • [43] Metrology for metalloproteins—where are we now, where are we heading?
    Claudia Swart
    Analytical and Bioanalytical Chemistry, 2013, 405 : 5697 - 5723
  • [44] Myopia Control 2020: Where are we and where are we heading?
    Bullimore, Mark A.
    Richdale, Kathryn
    OPHTHALMIC AND PHYSIOLOGICAL OPTICS, 2020, 40 (03) : 254 - 270
  • [45] Amyloidosis-Where Are We Now and Where Are We Heading?
    Picken, Maria M.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2010, 134 (04) : 545 - 551
  • [46] Treatments of trimethylaminuria: where we are and where we might be heading
    Schmidt, Aaron C.
    Leroux, Jean-Christophe
    DRUG DISCOVERY TODAY, 2020, 25 (09) : 1710 - 1717
  • [47] Analytical Nanoscience and Nanotechnology: Where we are and where we are heading
    Laura Soriano, Maria
    Zougagh, Mohammed
    Valcarcel, Miguel
    Rios, Angel
    TALANTA, 2018, 177 : 104 - 121
  • [48] Aligner biomechanics: Where we are now and where we are heading for
    Castroflorio, Tommaso
    Parrini, Simone
    Rossini, Gabriele
    JOURNAL OF THE WORLD FEDERATION OF ORTHODONTISTS, 2024, 13 (02) : 57 - 64
  • [49] Epigenetic therapy of hematological malignancies: where are we now?
    Popovic, Relja
    Shah, Mrinal Y.
    Licht, Jonathan D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2013, 4 (02) : 81 - 91
  • [50] Photodynamic therapy in urology: What can we do now and where are we heading?
    Bozzini, G.
    Colin, P.
    Betrouni, N.
    Nevoux, P.
    Ouzzane, A.
    Puech, P.
    Villers, A.
    Mordon, S.
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2012, 9 (03) : 261 - 273
12345